Hi Stickshift.
...so chipping away at the trade shows is the best way forward for BlastX to be used most appropriately because that is the only way into the hospitals?
Although the fact its primary effectiveness is in surgical situations need not preclude incorporating it into regular household products ?
Again my thinking is perhaps too simplistic, but I had thought to compete with the Dettols and iodines, it simply needs to be an effective antibacterial able to match the price of competitors, with a point of difference to give it a marketing edge over them.
I am not averse to the slow road, I just felt there might be other opportunities to broaden awareness and drive uptake.
...3M has exclusive global partnerships rights to BlastX for three years (either from November 2018 when the deal was signed or from January 2019 when the NXS team handed over ) so perhaps the theorising is a bit pointless .
Thank you for your perspective which sounds knowledgeable : )
Cheers
Hi Stickshift. ...so chipping away at the trade shows is the...
Add NXS (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
31.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $90.42M | |||
| Open | High | Low | Value | Volume |
| 31.0¢ | 32.0¢ | 31.0¢ | $42.92K | 137.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 6 | 74400 | 31.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 32.0¢ | 7331 | 2 |
View Market Depth
| Last trade - 16.10pm 30/04/2024 (20 minute delay) ? |
|
|||||
|
Last
31.5¢ |
Change
0.000 ( 1.19 %) |
||||
| Open | High | Low | Volume | ||
| 31.5¢ | 31.5¢ | 31.0¢ | 27217 | ||
| Last updated 15.43pm 30/04/2024 ? | |||||
| NXS (ASX) Chart |